Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

USANTIBIOTICS — Lobbying — Receipts Report

LD-2 disclosure · 2nd Quarter - Termination

USANTIBIOTICS

via RUBIN, TURNBULL & ASSOCIATES

2nd Quarter (Apr 1 - June 30) · 2026Posted Jul 18, 2026Filing document ↗LDA record ↗

Income$90Kfee reported

Client

Name: USANTIBIOTICS
Description: Pharmaceutical manufacturer
Location: Tennessee · United States of America

Registrant

Firm: RUBIN, TURNBULL & ASSOCIATES
Description: Public affairs consulting firm.
Location: Tallahassee, Florida, United States of America

Lobbying activities

1 issue

Pharmacy
Advocate on issues related to pharmaceuticals and drug regulation.
LobbyistsHEATHER TURNBULL · mr WILLIAM DAVID RUBIN · MICHAEL BURLEY · KATELYN SCHULTZ

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.